Lars Kyhn Rasmussen

USPTO Granted Patents = 43 (Patent Applications = 13)

CIPO Patents = 2 (Patent Applications = 11)

EPO Patents = 22 (Patent Applications = 29)

Average Co-Inventor Count = 5.5

ph-index = 7

Forward Citations = 146(Granted Patents)

Location History:

København S, DK (2012)
Brønshøj, DK (2015)
Bronshoj, DK (2017)
Valby, DK (2018 - 2020)
Vanløse, DK (2015 - 2023)

Company Filing History:

Mindimmune Therapeutics, Inc.

4. 1 out of 832,680

Other

patents

Years Active: 2012-2023

Loading Chart...

43 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11851425 - Combination treatments comprising administration of 1H-pyrazolo[4,3-B]pyridines (2023-12-26),

2. 11634416 - Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines (2023-04-25),

3. 11535611 - Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors (2022-12-27),

4. 11491140 - 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors (2022-11-08),

5. 11472810 - Imidazopyrazinones as PDE1 inhibitors (2022-10-18),

6. 11104680 - 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-ones as PDE1 inhibitors (2021-08-31),

7. 11026924 - 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors (2021-06-08),

8. 11026923 - 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors (2021-06-08),

9. 10912773 - Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors (2021-02-09),

10. 10905688 - Combinations comprising substituted imidazo[1,5-α]pyrazinones as PDE1 inhibitors (2021-02-02),

11. 10858362 - Imidazopyrazinones as PDE1 inhibitors (2020-12-08),

12. 10806718 - 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors (2020-10-20),

13. 10766893 - 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors (2020-09-08),

14. 10703751 - Amino-imidazopyridine derivatives as Janus kinase inhibitors and pharmaceutical use thereof (2020-07-07),

15. 10689379 - Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors (2020-06-23),

Certainly! Here's the article about inventor Lars Kyhn Rasmussen:

Title: Lars Kyhn Rasmussen: Pioneering Innovation in Technology

Introduction:

Lars Kyhn Rasmussen is a visionary inventor hailing from Vanløse, Denmark. With a dedication to driving innovation and creating a brighter future through his groundbreaking inventions, he has cemented his status as a true pioneer in the realm of technology.

Latest Patents:

With an impressive portfolio of 43 patents to his name, Lars Kyhn Rasmussen's latest advancements include revolutionary combination treatments comprising the administration of 1H-pyrazolo[4,3-B]pyridines. These compounds serve as PDE1 inhibitors alongside secondary compounds, presenting a significant breakthrough in the treatment of neurodegenerative, cognitive, and psychiatric disorders.

Career Highlights:

Throughout his illustrious career, Lars Kyhn Rasmussen has left an indelible mark on the technology landscape. Notably, he has contributed his innovative expertise to esteemed companies such as H. Lundbeck A/S and Mindimmune Therapeutics, Inc., where his inventive spirit has flourished.

Collaborations:

Collaboration fuels innovation, and Lars Kyhn Rasmussen has worked closely with distinguished colleagues such as Mikkel Jessing and Morten Langgård. Together, they have synergized their talents to push the boundaries of technological advancement and create impactful solutions for pressing global challenges.

Conclusion:

In conclusion, Lars Kyhn Rasmussen's relentless pursuit of innovation and his unwavering commitment to shaping a better tomorrow through his inventions exemplify the pinnacle of technological brilliance. His pioneering work continues to inspire and pave the way for future generations of inventors, solidifying his legacy as a trailblazer in the world of technology.

This text is generated by artificial intelligence and may not be accurate.